

PHILLIP RESEARCH SDN BHD

199001007125 (198695-X)

B-18-6, Megan Avenue II, No 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur. Tel No: 03-2783 0300

Morning Pole Position

All market data as at previous trading day

Market indices

Indices		Last	Daily	/ chg	YTD chg%	6
Local						
FBMKLCI	1,41	5.10		14.74	-9.7	2
FBMEmas	10,04	3.97		69.07	-11.1	
FBMSHA	10,04			10.16	-18.0	
FBMSCAP	13,87			65.13	-11.9	
FBMACE		24.95		-28.22	-26.4	
F4GBM		3.96		7.25	-7.5	
F4GBMS		26.80		1.38	-15.8	
Funds Flows					uy (MYR'm)
Local Institutio	ons				60.	
Local Retails					-6.	
Foreign					-54.	
Foreign						
Dow Jones	30,42	23.81		-99.99	-16.2	8
S&P 500		95.16		-24.82	-22.4	
Nasdaq	10,68			-91.89	-31.7	
FTSE		24.99		-11.75	-6.2	
Hang Seng	16,51			-403.3	-29.4	
Nikkei	27,25			101.24	-5.3	
Shanghai Cl		4.38		-36.58	-16.3	
Strait Times		22.80		-3.08	-3.2	
Currencies	0,01			0.00		<u> </u>
BNM Middle	Pata	Las	t D/	aily chg	YTD 9	1
(5pm)	Nale	Las	L Da	any cng		0
USD / MYR		4.7240)	0.0090	13.4	2
GBP / MYR		5.321		-0.0036		
JPY100 / MYF	2	3.161		0.0029		
EUR/MYR		4.6376		0.0032		
SGD / MYR		3.3193		0.0006		
CNY / MYR		0.6542		-0.0008		
AUD / MYR		2.9752		0.0147		
Bond Yield I	Movemer	nts				
			rield	Dailv	Change (b	ps
MGS	3- year	·	3.94			4
	10- year		4.45			-1
GII	3- year		3.88			-8
	10- year		4.57			1
UST	2- year		4.55			12
	10- year		4.14			13
Commoditie	s					
		Last		Dail	y Daily	
					g chg %	

| 20th October 2022 |

FBMKLCI and statistics



arket Turnover

2,234	
1,717	
	2,234 1,717

Top 5 Value	Last	Daily chg %	Value (MYR m)
IHH	6.100	2.18	91.750
PCHEM	8.630	0.94	89.184
PBBANK	4.340	3.33	72.971
CIMB	5.390	2.67	63.611
TOPGLOV	0.725	-2.03	52.932

Top 5 Gainers	Last	Daily chg %	Value (MYR m)
PERMAJU-PA	0.010	100.00	0.001
CAP	0.010	100.00	0.121
VSOLAR	0.010	100.00	0.006
DOLPHIN	0.020	33.33	0.000
KEYASIC	0.045	28.57	0.329

Top 5 Losers	Last	Daily chg %	Value (MYR m)	
EAH	0.005	-50.00	0.013	
FOCUS-PA	0.005	-50.00	0.002	
EDUSPEC	0.010	-33.33	0.368	
XDL	0.015	-25.00	0.006	
SERBADK	0.015	-25.00	0.039	

.14		13	Top 5 DBT	Value	Volume	Price
				(MYR m)	(m shares)	(MYR)
			CHINHIN	99.998	41.666	2.7
	aily	Daily	UMW	28.135	8.500	3.33
	chg	chg %	HLBANK	19.817	0.950	20.86
	107	2.67	IJM	10.990	7.000	1.55
	2.39	2.65	RAPID	4.896	0.360	14.78
-22	2.85	-1.38				

Gold (spot) 1,629.16 Source: Treasury.gov, Bursa and BNM

4,118.00

92.57

CPO (3rd month)

Brent (1st month)

Market Pulse



Source: Chart created using tradingview.com's tools, PRSB

The KLCI index continued its rally to close at 1,415.10 pts with +14.74 pts (+1.05%). KLCI constituents saw 19 gainers and 11 losers, with Public Bank and CIMB gaining 3.33% and 2.67%, respectively. On the broader market, sentiment is mixed as gainers slightly outpaced losers 437 to 426, while 382 counters were unchanged.

Meanwhile, the U.S. market snapped its two-day rally as positive news on company earnings was offset by a renewed rise in bond yields and a poorly received US 20-year Treasury auction.

With Morgan Stanley and Nomura calling a bottom in Asian stocks in the next few weeks, we believe foreign funds will flow into Malaysia. Although local investors' sentiment may continue to be mixed today pending the announcement of the polling date, KLCI breached the 1,408.83 level yesterday which now becomes the support level for today. Should the buying momentum continue, KLCI may reach 0.236 Fibonacci level at 1,431.67, which is supported by the rising RSI. However, we think KLCI will close with an indecisive candle today as investors continue to seek market directions ahead of GE15. Our Picks in Exhibit 1.

Ticker	Rating	Price (MYR)	TP (MYR)	Upside (%)
BAUTO MK	Buy	1.93	2.45	26.94
GUAN MK	Outperform	2.12	2.78	31.13
QLG MK	Outperform	5.06	5.77	14.03
OHB MK	Buy	0.820	1.24	51.22
GAM MK	Outperform	3.65	4.30	17.81
CWH MK	Outperform	1.68	2.00	19.05
SCT MK	Outperform	1.60	1.73	8.12
	GUAN MK QLG MK OHB MK GAM MK CWH MK	BAUTO MK GUAN MKBuy OutperformQLG MK OHB MK GAM MKOutperform Outperform Outperform Outperform	BAUTO MK GUAN MKBuy Outperform1.93 2.12QLG MK OHB MKOutperform5.06 0.820OHB MK GAM MKBuy Outperform0.820 3.65 0.820CWH MKOutperform1.68	BAUTO MK GUAN MKBuy Outperform1.93 2.122.45 2.78QLG MK OHB MKOutperform Buy5.06 0.8205.77 1.24OHB MK GAM MKOutperform Outperform3.65 3.654.30 2.00

Pentamaster Corporation	PENT MK	Buy	3.81	5.26	38.06
Formosa Prosonic Industries	FOR MK	Buy	2.98	3.92	31.54
Kerjaya Prospek Group	KPG MK	Outperform	1.20	1.39	15.83
MMS Ventures	MMSV MK	Buy	0.660	1.20	81.82
FM Global Logistics Holdings	FMH MK	Buy	0.525	0.82	56.19
Hibiscus Petroleum	HIBI MK	Buy	0.88	1.32	50.00
OSK Holdings	OSK MK	Buy	0.86	1.12	30.23
UWC	UWC MK	Buy	3.57	5.03	40.90
Dayang Enterprise	DEHB MK	Buy	1.11	1.44	29.73
CTOS Digital	CTOS MK	Buy	1.31	1.78	35.88
Ancom Nylex	ANC MK	Buy	0.98	1.24	27.18
BP Plastics Holdings	BPP MK	Buy	1.40	1.80	28.57
CCK Consolidated Holdings	CCK MK	Outperform	0.61	0.71	17.36
Vitrox Corp Bhd	VITRO BHD	Buy	7.05	7.88	11.70
Pecca Group BHd	PECCA MK	Buy	0.84	1.16	38.32
Nova Wellness Group Bhd	NOVA MK	Outperform	0.87	1.07	22.41
Duopharma Biotech Bhd	DBB MK	Outperform	1.37	1.44	5.11
Mega First Corp	MFCB MK	Outperform	3.29	3.63	10.18
ETF					
MyETF Dow Jones U.S. Titans 50	METFUS50 MK	Buy	USD 1.65	USD 1.93	17.12
MyETF MSCI SEA Islamic Dividend	MEMSID MK	Buy	0.79	0.92	16.28
Principal FTSE ASEAN 40 Malaysia ETF	CIMBA40 MK	Buy	1.64	1.80	9.73
Principal FTSE China 50 ETF	CIMBC25 MK	Buy	1.15	1.39	21.17
TradePlus HSCEI Daily (2x) Leveraged Tracker	HSCEI2XL MK	Strong Buy	0.48	0.85	77.89
TradePlus NYSE FANG+ Daily (-1x) Inverse Tracker	FANG1XI MK	Buy	1.90	1.86	-2.11

Source: Bursa, Bloomberg, PRSB, price as of 19th October 2022

• Slower export growth expected ahead as base effect dissipate in September, say economists.

Malaysia's total export rose 30.1% year-on-year (y-o-y) in September to RM144.31 billion, supported by external demand for electrical and electronics (E&E) and oil and gas products. However, the figure was below *Bloomberg* consensus forecast of 31.5% and also below the 31.2% growth expected by economists polled by *Reuters*. It was also lower than the export growth achieved in August of 48.2%. (Source: <u>TheEdgeMarkets</u>)

Global news highlights

• Fed Says Economy Grew Modestly But Recession Worry Dims Outlook.

"Outlooks grew more pessimistic amidst growing concerns about weakening demand," the Fed said Wednesday in its Beige Book report, published two weeks before each meeting of the policy-setting Federal Open Market Committee. "Several Districts reported a cooling in labor demand, with some noting that businesses were hesitant to add to payrolls amid increased concerns of an economic downturn." (Source: <u>Bloomberg</u>)

• Mortgage Rates in US Extend Climb to 6.94%, Highest Since 2002.

The contract rate on a 30-year fixed mortgage jumped another 13 basis points to 6.94% in the week ended Oct. 14, marking the ninth-straight increase, according to Mortgage Bankers Association data released Wednesday. (Source: <u>Bloomberg</u>)

• A £52 Billion Jump in Mortgage Costs Fuels Risk for UK Lenders.

A surge in bad loans awaits UK banks as higher interest rates saddle homeowners with an estimated £52 billion (\$58.6 billion) of added mortgage payments over the next three years, an analyst warned as he downgraded his ratings on several lenders. The jump in costs will help push the personal debt service burden toward about 10% of post-tax income and further into the "dangerous territory" traditionally associated with large increases in impairments, Keefe, Bruyette & Woods analyst Ed Firth wrote in a note to clients on Wednesday. (Source: <u>Bloomberg</u>)

• Philippine Central Bank Ready to Use Tools to Smooth Peso Swings.

The Philippine central bank stands ready to use other tools to curb the peso's volatility, according to an official, as the authority's intervention in the currency market is less than its peers. Bangko Sentral ng Pilipinas is "prepared to utilize other tools to respond to fluctuations in exchange rate and to ensure that legitimate demand for foreign currency is satisfied," Senior Assistant Governor Iluminada Sicat told lawmakers at a Senate hearing Wednesday. (Source: <u>Bloomberg</u>)

Corporate news

• Axis REIT 3Q income jumps 12.5%, declares 2.45 sen DPU.

Axis Real Estate Investment Trust's (REIT) net property income (NPI) in the third quarter ended Sept 30, 2022 (3QFY22), climbed 12.54% to RM61.49 million from RM54.64 million a year earlier, on the back of rental income from newly-acquired properties. A third interim income distribution of 2.45 sen per unit will be paid on Nov 30, Axis REIT said in a bourse filing on Wednesday (Oct 19). Together with the 2.42 sen per unit and 2.55 sen per unit distributed for 1Q and 2QFY22, the company's year-to-date distribution per unit (DPU) stands at 7.42 sen. (Source: <u>TheEdgeMarkets</u>)

• Eight rail stations designated as emergency response centres, says Prasarana.

Prasarana Malaysia Bhd has designated eight rail stations as emergency response centres under its Rapid KL Safety Point (RSP) pilot project. The selected stations will provide emergency assistance for those who need it. The eight rail stations are the Kampung Batu MRT station, Pasar Seni LRT and MRT stations, Masjid Jamek LRT station (Kelana Jaya and Ampang routes), KL Sentral LRT station, KLCC LRT station and Bukit Bintang MRT station. (Source: <u>TheEdgeMarkets</u>) • Bursa seeks public feedback on proposed amendments to Main Market Listing Requirements on REITs and ETFs with waqf.

Bursa Malaysia Securities Bhd seeks public feedback on the proposed amendments to the Main Market Listing Requirements in relation to listed real estate investment trusts (REITs) and exchange-traded funds (ETFs) with waqf feature. In a statement on Wednesday (Oct 19), the regulator said the proposed waqf amendments are meant to complement the Securities Commission Malaysia's initiatives to broaden the range of Islamic capital market products which support socio-economic development, greater public good and wealth distribution in the Malaysian capital market. (Source: <u>TheEdgeMarkets</u>)

DISCLAIMER

Legal and Regulatory Notices (Electronic Communications) © 2018 PRSB.

Important disclosures

This research report is strictly confidential and has been prepared for information purposes only by Phillip Research Sdn Bhd ("PRSB"), a subsidiary of Phillip Capital Holdings Sdn Bhd ("PCH") and is meant for circulation to its clients and clients of other subsidiaries companies of PCH particularly Phillip Mutual Berhad ("PMB"), Phillip Capital Management Sdn Bhd ("PCM"), Phillip Wealth Planners Sdn Bhd ("PWP") and Phillip Capital Sdn Bhd ("PCSB") (collectively refer to as Phillip Group other licensed intermediaries ("PGOLI")) only or such other persons as may be deemed eligible to receive such research report, information or opinion contained herein. Neither the publication/communication nor any portion hereof may be reprinted, distributed, sold, resold, redistributed, copied, reproduced, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of PRSB.

The policy of PRSB is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts never receive compensation from companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a disclosable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of PRSB's research, PGOLI activities such as fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and research business lines are distinct from one another. This means that PRSB is not part of and does not report to any of PGOLI. Accordingly, PGOLI does not supervise nor control the activities of PRSB's research analysts. PRSB's research analysts report to the Head of Research, who in turn report to PRSB's senior management.

PRSB and PGOLI have in place internal controls designed to manage conflicts of interest that may arise as a result of PGOLI engaging in fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and PRSB activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with PRSB and PGOLI's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among PRSB's research personnel, fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, and financial planning, PGOLI's financial product issuers and PRSB's research analysts do not compromise the integrity and independence of PRSB's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities up to the date of the publication of this research report.

Unless specified otherwise, PRSB did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, PRSB does not own a material disclosable position, and does not make a market, in the securities.

We hereby certify that the views expressed in this research report accurately reflect our views about the securities and/or the issuers and that no part of our compensation were or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. We hereby confirm that our analyst(s) has/have not been placed under any undue influence, intervention or pressure by any person(s) in compiling this research report. This report is prepared without any intention to raise, lower or maintaining the price of the securities covered or to induce the recipient to buy or sell the securities covered. In addition, our analyst(s) included herein attest that he/she/they was/were not in possession of any

material, non-public price sensitive information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), we are not aware of any material conflict of interest.

Key to PRSB investment ratings:

Equity:

BUY: Total stock return (including dividends) expected to exceed 20% annually;

O-PF: Total expected return below 20% annually but exceeding market return;

U-PF: Total expected return positive but below market return;

SELL: Total return expected to be negative.

For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

ETFs (Criteria applies to rating assignments from 16th December 2019):

STRONG BUY: Total return (including dividends) expected to exceed 20% annually;

BUY: Total expected return below 20% but exceed 5% or then 1-year rate, whichever is higher;

SELL: Total return of not more than 5% or then 1-year rate, whichever is higher.

The ratings are based on the forecast total return (including dividends) over the next 12 months. Funds:

The rating a mathematical scoring system that include risks (standard deviation, Sharpe Ratio) and returns (1year, 3-year, 5-year and consistency)BUY: Total return (including income distribution) is positive and above peers' average while risk factors are low;

O-PF: Total return is positive and above peers' average but has higher risk factors; SELL: Total return is negative.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: Phillip Research Sdn Bhd, B-18-6, Block B Level 18, Megan Avenue II, 12 Jalan Yap Kwan Seng, 50450 Kuala Lumpur, Malaysia.

The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject PRSB and/or its associate companies to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of PRSB at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person (include but not limited to Financial Planners and Marketing Representative or a non-analyst), such views and opinions may not correspond to the published view of PRSB. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. PRSB, and PGOLI do not accept any responsibility and cannot be held liable for any person's use of, or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, PRSB accepts no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, PRSB, PGOLI and their respective affiliates or companies or individuals connected with PRSB may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that PRSB, PGOLI and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation. Disclosures therein include the position of PRSB and PGOLI only. Unless specified otherwise, PRSB did not receive any compensation or other benefits from the subject company covered in this publication/communication.

The analysts/contributors to this publication/communication may be employed by any relevant PGOLI entity, which is different from the entity that distributes the publication/communication in the respective jurisdictions.

PRSB, PGOLI and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. PGOLI may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

Investors should not consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. PRSB produces a number of different types of research product including, among others, fundamental analysis and quantitative analysis; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. PRSB and PGOLI publishes research product in a number of different ways including the posting of product on the PGOLI portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Any figure, strategy or index created and published for illustrative purposes within this report is not intended for "use" as a "benchmark".

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

With respect to Fixed Income Research: Recommendations fall into two categories: tactical, which typically last up to three months; or strategic, which typically last from 6-12 months. However, trade recommendations may be reviewed at any time as circumstances change. 'Stop loss' levels for trades are also provided; which, if hit, closes the trade recommendation automatically. Prices and yields shown in recommendations are taken at the time of submission for publication and are based on either indicative Bloomberg, Reuters or PGOLI prices or yields at that time. The prices and yields shown are not necessarily those at which the trade recommendation can be implemented.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via PhillipCapital Group entity in your home jurisdiction.